Palivizumab indications and usage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Palivizumab}} {{CMG}}; {{AE}} {{SS}} ==Indications And Usage== Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respir...")
 
No edit summary
 
Line 4: Line 4:


==Indications And Usage==
==Indications And Usage==
Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD) [see Clinical Studies (14)].
Synagis is indicated for the prevention of serious lower respiratory tract disease caused by [[respiratory syncytial virus]] ([[respiratory syncytial virus|RSV]]) in children at high risk of [[respiratory syncytial virus|RSV]] disease. Safety and efficacy were established in children with [[bronchopulmonary dysplasia]] (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD) [see Clinical Studies (14)].


The following point should be considered when prescribing Synagis:
The following point should be considered when prescribing Synagis:
The safety and efficacy of Synagis have not been established for treatment of RSV disease.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e35c4c8-bf56-458f-a73c-8f5733829788#nlm34089-3 | publisher =  | date =  | accessdate = 8 January 2014 }}</ref>
The safety and efficacy of Synagis have not been established for treatment of [[respiratory syncytial virus|RSV]] disease.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8e35c4c8-bf56-458f-a73c-8f5733829788#nlm34089-3 | publisher =  | date =  | accessdate = 8 January 2014 }}</ref>
==References==
==References==
{{Reflist}}
{{Reflist}}

Latest revision as of 04:26, 8 January 2014

Palivizumab
SYNAGIS® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Indications And Usage

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD) [see Clinical Studies (14)].

The following point should be considered when prescribing Synagis: The safety and efficacy of Synagis have not been established for treatment of RSV disease.[1]

References

  1. "SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [MEDIMMUNE, LLC]". Retrieved 8 January 2014.

Adapted from the FDA Package Insert.